Having facilites in Ann Arbor MI and in Cambridge, MA., Vericel Corporation (NASDAQ:VCEL) was, until 2014, doing business as Aastrom Biosciences, Inc. A regenerative medicine company engaged in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases, the firm develops patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two cell therapy products in theUS: MACI® (autologous cultured chondrocytes on porcine collagen membrane) - a third generation autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® -- cultured epidermal autografts -- is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing an additional cell product. Deisgnated Ixmyelocel-T, the profuct is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Vericel is also now addressing development of novel therapies for the treatment of patients with autologous (patients own) cells.
